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révélé que l’architecture cellulaire n’est pas bien organisée à trois 
jours alors que celle-ci semble mature à une semaine.
Ces résultats démontrent, globalement, que l’organisation 
architecturale des cardiomyocytes, nécessaire pour des régulations 
énergétiques ef caces, se met en place entre trois et sept jours 
chez la souris.
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Cyclic nucleotides mediated signaling determines the regulation 
of many cardiac function. It is generally admitted that the cyclic 
nucleotides degradation is due to phosphodiesterases. Recently, 
cAMP and cGMP were also shown to be extruded from the cell by 
an active ef ux transporter, called MRP4. We investigated whether 
inhibition of MRP4 may independently control cyclic nucleotides 
levels and modify functions related to cyclic nucleotides signalling 
pathways in cardiac myocytes.
Methods — We used silencing RNA or adenovirus encoding MRP4 
shRNA (Ad-ShMRP4) to inhibit MRP4 expression in rat cardiomyocytes 
in vitro. We then performed physiological evaluation of cardiac 
morphology and function in knock-out MRP4 mice. As a model of 
adrenergically induced cardiac hypertrophy, miniosmotic pumps 
containing isoproterenol delivering 20 ìg/g/day for 2 weeks were 
implanted subcutaneously into 3-months old MRP4 KO and wild type 
mice. As a model of physiological hypertrophy, animals were housed 
in a cage with free access to a running monitored wheel.
Results — MRP4 is present in human, mouse and rat cardiomyocytes 
and over-expressed in case of increased cardiac intracellular cAMP. 
Using a FRET technique MRP4 inhibition was shown to increase 
intracellular cAMP level. Adult rat cardiomyocytes infected with 
Ad-shMRP4 demonstrated a signi cant increase in the calcium 
current density and in cell size compared to cells infected with 
the negative control Ad-shLuciferase, suggesting an activation 
of the cAMP/PKA pathway. While unchallenged young (3 months) 
MRP4 KO mice displayed normal cardiac parameters, MRP4 KO mice 
progressively developed signi cant cardiac hypertrophy by 9-12 
months of age (HW/BW ; 5.15 vs 4.46 in WT mice). Isoproterenol-
treated MRP4 KO mice displayed a signi cant increase in cardiac 
hypertrophy compared to stimulated WT mice (HW/BW: 6±0.38 vs 
5.29±0.34 ; p=0.001). In contrast to the regulation of pathological 
cardiac hypertrophy, MRP4 inhibition did not affect the physiological 
cardiac growth response associated with physical training (HW/
BW: 4.83±0.01, vs 4.84±0.13, p=NS), indicating the absence of a 
regulatory role of MRP4 in physiological cardiac hypertrophy.
Conclusion — These results reveal a unique and important function 
for MRP4 in stress-dependent cardiac growth by controlling cyclic 
nucleotides signalling pathways in cardiomyocytes.
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The regulation of arterial contractility is essential for blood pressure 
control. The GTPase RhoA promotes vasoconstriction by modulating 
the cytoskeleton of vascular smooth muscle cells. Whether other 
Rho/Rac pathways contribute to blood pressure regulation remains 
unknown. We have previously demonstrated that vav2 null mice 
suffered from serious defects in the cardiovascular system of, 
including tachycardia, systemic arterial hypertension, extensive 
cardiovascular remodelling, heart  brosis, and loss of kidney 
homeostasis. By studying this hypertensive knockout mouse lacking 
the Rho/Rac activator Vav2, we have discovered a new pathway 
composed of Vav2, the GTPase Rac1, and the serine/threonine kinase 
Pak that is critical for nitric oxide—triggered blood vessel relaxation 
and normotensia. This pathway mediates the Pak—dependent 
inhibition of phosphodiesterase type 5, a process that favors 
the inactivation of the RhoA pathway and the depolymerization 
of the F—actin cytoskeleton in vascular smooth muscle cells. 
The inhibition of phosphodiesterase type 5 requires its physical 
interaction with autophosphorylated Pak1 but, unexpectedly, 
occurs without detectable transphosphorylation events between 
those two proteins. The administration of phosphodiesterase type 
5 inhibitors prevents the development of the hypertension and the 
cardiovascular disease in Vav2—de cient animals, demonstrating 
the key role of this signaling route in blood pressure regulation. 
Taken together, these results unveil the cause of the cardiovascular 
phenotype of Vav2 knockout animals, identify a new Rac1/Pak1 
signaling element, and provide a mechanistic framework to better 
understand blood pressure control in physiological and pathological 
states.
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Chronic agonist stimulation of the β2 Adrenergic Receptors (β2ARs) 
leads to their lysosomal traf cking and degradation. Previous 
studies demonstrated that agonist-induced β2AR ubiquitination is 
necessary for lysosomal targeting and degradation of the receptor. 
We have now found that the de-ubiquitinating enzymes USP33 and 
USP20 are recruited to the β2AR complexes, by using cellular co-
immunoprecipitation assays. This led to our hypothesis that USP33 
